Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

  • LAST PRICE
    3.7300
  • TODAY'S CHANGE (%)
    0.4100 (12.3494%)
  • Bid / Lots
    3.7200/ 2
  • Ask / Lots
    3.9000/ 31
  • Open / Previous Close
    3.2500 / 3.3200
  • Day Range
    3.1906
    4.0700
  • 52 Week Range
    2.6600
    18.2400
  • Volume
    2,852,473

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 1, 2024

      Show headlines and story abstract

    • 7:04PM ET on Friday Nov 01, 2024 by Dow Jones
      Companies Mentioned: ZNTL

      Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis(R) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company's common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Peers Headlines